Literature DB >> 22136739

Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.

S E Smith1, E V Kurbatova, J S Cavanaugh, J P Cegielski.   

Abstract

Following the World Health Organization's endorsement of the Xpert® MTB/RIF assay, which rapidly and simultaneously diagnoses tuberculosis (TB) and detects resistance to rifampin (RMP), the question arises to what extent RMP resistance is an adequate marker for multidrug-resistant TB (MDR-TB). A retrospective analysis of data from >81 countries and subnational settings demonstrated that >40% of RMP-resistant isolates from new TB cases did not display resistance to isoniazid (INH) in settings with relatively low MDR-TB prevalence (one third of all countries and subnational settings). Results indicated the need for INH susceptibility testing in addition to RMP susceptibility testing.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22136739      PMCID： PMC4593497          DOI： 10.5588/ijtld.11.0445

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  2 in total

1.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

2.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321
  2 in total
  31 in total

1.  Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.

Authors:  E V Kurbatova; J S Cavanaugh; N S Shah; A Wright; H Kim; B Metchock; A Van Deun; L Barrera; F Boulahbal; E Richter; N Martín-Casabona; F Arias; I Zemanova; F Drobniewski; A Santos Silva; C Coulter; R Lumb; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012       Impact factor: 2.373

2.  Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens.

Authors:  Sabine Hofmann-Thiel; Nikolay Molodtsov; Uladzimir Antonenka; Harald Hoffmann
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

Review 3.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 4.  The medical and surgical treatment of drug-resistant tuberculosis.

Authors:  Gregory L Calligaro; Loven Moodley; Greg Symons; Keertan Dheda
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

5.  Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.

Authors:  Y F van der Heijden; F Karim; G Mufamadi; L Zako; T Chinappa; B E Shepherd; F Maruri; M-Y S Moosa; T R Sterling; A S Pym
Journal:  Int J Tuberc Lung Dis       Date:  2017-06-01       Impact factor: 2.373

6.  The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay.

Authors:  M Barnard; N C Gey van Pittius; P D van Helden; M Bosman; G Coetzee; R M Warren
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

7.  Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa.

Authors:  Lesley Scott; Anura David; Lara Noble; Matilda Nduna; Pedro Da Silva; Andrew Black; Francois Venter; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

Review 8.  Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren
Journal:  Lancet Respir Med       Date:  2014-03-24       Impact factor: 30.700

9.  Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.

Authors:  Anne F Luetkemeyer; Michelle A Kendall; Xingye Wu; Maria Cristina Lourenço; Ute Jentsch; Susan Swindells; Sarojini S Qasba; Jorge Sanchez; Diane V Havlir; Beatriz Grinsztejn; Ian M Sanne; Cynthia Firnhaber
Journal:  J Clin Microbiol       Date:  2014-01-15       Impact factor: 5.948

10.  Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria.

Authors:  Lana Dinic; Patrick Akande; Emmanuel Oni Idigbe; Agatha Ani; Dan Onwujekwe; Oche Agbaji; Maxwell Akanbi; Rita Nwosu; Bukola Adeniyi; Maureen Wahab; Chindak Lekuk; Chioma Kunle-Ope; Nkiru Nwokoye; Phyllis Kanki
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.